Global /Taiwan /Healthcare /Biotechnology /6549

TaiwanJ Pharmaceuticals Co., Ltd.

6549

• TPEX: 6549 • Delayed

8.30TWD 4.7%

0.2623 USD

As of 20 June 2026, TaiwanJ Pharmaceuticals Co., Ltd. has a market cap of $20.09M USD, ranking #37051 globally and #2236 in Taiwan. It ranks #3329 in the Healthcare sector, and #651 in the Biotechnology industry.

Global Rank

37051

Country Rank

2236

Sector Rank

3329

Industry Rank

651

Key Stats

Market Cap

$20.09MUSD

635.37M TWD

Enterprise Value

$17.99MUSD

569.33M TWD

EBITDA (TTM)

-$770.18KUSD

-24.37M TWD

Net Income (TTM)

-$769.82KUSD

-24.34M TWD

PB Ratio

9.0

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Hung-Chang Yuan open_in_new

Employees

Founded

2011

Website

taiwanj.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
4.7%	-14%	5.1%	-11%	-2.1%	1.2%	-1.9%	-73%	-46%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6549 景凱生物科技股份有限公司 ISIN: TW0006549009 Shares Out.: Shares Outstanding: 80.122M¹ Shares Float: 66.974M² TV: TradingView: TPEX: 6549 SA: Stock Analysis: TPEX: 6549 YF: Yahoo Finance: 6549.TWO GF: Google Finance: TPEX: 6549 BA: Barron's: 6549 MS: Morningstar: ROCO: 6549	8.30 TWD	TV: TradingView: TPEX: 6549 SA: Stock Analysis: TPEX: 6549 YF: Yahoo Finance: 6549.TWO GF: Google Finance: TPEX: 6549 BA: Barron's: 6549 MS: Morningstar: ROCO: 6549

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About TaiwanJ Pharmaceuticals Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.46B 172.76B TWD 27K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 8K%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 5K%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$726.25M 22.97B TWD 4K%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$600.25M 18.98B TWD 3K%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$571.26M 18.06B TWD 3K%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 908K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 796K%	19.0	United States
argenx SE EBR: ARGX	$47.43B 41.39B EUR 236K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 220K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 210K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.88B 33.71B CHF 208K%	37.2	Switzerland

chevron_leftBack